Loading company…
German biotech developing lipid nanoparticle technology for organ-specific delivery of mRNA therapies.
Founded in 2014 in Germany, Pantherna Therapeutics GmbH develops lipid nanoparticle technologies for organ-specific and cell-selective delivery of mRNA-based therapeutics. Its PTXmRNA and PTX LNP technologies target conditions such as pulmonary edema, and the company works through partnerships and collaborations with pharmaceutical and biotech companies. In January 2022 it raised EUR 4 million in Series B funding, co-led by High-Tech Gründerfonds and Riesner Verwaltungs GmbH, at a valuation of EUR 18.823 million. CEO Klaus Giese leads the company.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in